Zai Lab (ZLAB) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ZLAB Stock Forecast

Zai Lab stock forecast is as follows: an average price target of $75.50 (represents a 193.77% upside from ZLAB’s last price of $25.70) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

ZLAB Price Target

The average price target for Zai Lab (ZLAB) is $75.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $101.00 to $50.00. This represents a potential 193.77% upside from ZLAB's last price of $25.70.

ZLAB Analyst Ratings

Buy

According to 3 Wall Street analysts, Zai Lab's rating consensus is 'Buy'. The analyst rating breakdown for ZLAB stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Zai Lab Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 27, 2024	Jack Lin	Morgan Stanley	-	-	111.60%	94.55%
Apr 21, 2022		Leerink Partners	-	-	135.54%	293.00%

Row per page

Go to

The latest Zai Lab stock forecast, released on Sep 27, 2024 by Jack Lin from Morgan Stanley, set a price target of $50.00, which represents a 111.60% increase from the stock price at the time of the forecast ($23.63), and a 94.55% increase from ZLAB last price ($25.70).

Zai Lab Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	1
Avg Price Target	-	$50.00	$50.00
Last Closing Price	$25.70	$25.70	$25.70
Upside/Downside	-100.00%	94.55%	94.55%

In the current month, the average price target of Zai Lab stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Zai Lab's last price of $25.70. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 27, 2024	Morgan Stanley	Overweight	Overweight	Hold
Apr 09, 2024	Bank of America Securities	Buy	Buy	Hold
Oct 26, 2023	Goldman Sachs	Buy	Buy	Hold

Row per page

Go to

Zai Lab's last stock rating was published by Morgan Stanley on Sep 27, 2024. The company gave ZLAB a "Overweight" rating, the same as its previous rate.

Zai Lab Financial Forecast

Zai Lab Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
Revenue	-	-	-	-	-	-	-	-	-	$69.23M	$68.86M	$62.80M	$62.60M	$57.54M	$48.18M	$46.72M	$44.17M	$43.10M	$36.94M	$20.10M	$15.09M	$14.65M	$10.99M	$8.22M	$4.65M
Avg Forecast	$128.50M	$122.30M	$117.00M	$112.30M	$107.69M	$102.24M	$93.16M	$75.24M	$72.14M	$66.41M	$70.48M	$65.12M	$62.79M	$53.75M	$47.13M	$44.58M	$47.89M	$43.77M	$27.41M	$17.66M	$25.45M	$15.83M	$-1.64M	$36.00K	$10.00M
High Forecast	$135.99M	$129.43M	$123.82M	$123.33M	$110.49M	$103.09M	$93.16M	$75.24M	$76.07M	$69.27M	$74.59M	$68.92M	$66.45M	$53.75M	$47.13M	$44.58M	$47.89M	$43.77M	$27.41M	$17.66M	$25.45M	$15.83M	$-1.64M	$36.00K	$10.00M
Low Forecast	$123.36M	$117.41M	$112.32M	$106.65M	$105.19M	$101.39M	$93.16M	$75.24M	$67.70M	$63.55M	$67.66M	$62.52M	$60.28M	$53.75M	$47.13M	$44.58M	$47.89M	$43.77M	$27.41M	$17.66M	$25.45M	$15.83M	$-1.64M	$36.00K	$10.00M
# Analysts	1	1	1	3	4	2	2	2	5	2	2	2	1	3	3	3	4	4	4	4	4	4	4	4	3
Surprise %	-	-	-	-	-	-	-	-	-	1.04%	0.98%	0.96%	1.00%	1.07%	1.02%	1.05%	0.92%	0.98%	1.35%	1.14%	0.59%	0.93%	-6.71%	228.28%	0.46%

Zai Lab's average Quarter revenue forecast for Dec 23 based on 5 analysts is $72.14M, with a low forecast of $67.70M, and a high forecast of $76.07M. ZLAB's average Quarter revenue forecast represents a 4.21% increase compared to the company's last Quarter revenue of $69.23M (Sep 23).

Zai Lab EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
# Analysts	1	1	1	3	4	2	2	2	5	2	2	2	1	3	3	3	4	4	4	4	4	4	4	4	3
EBITDA	-	-	-	-	-	-	-	-	-	$-83.57M	$-89.50M	$-78.43M	$-136.00M	$-126.36M	$-96.86M	$-77.75M	$-209.95M	$-94.78M	$-161.80M	$-231.46M	$-75.14M	$-62.55M	$-79.54M	$-46.86M	$-45.14M
Avg Forecast	$-128.50M	$-122.30M	$-117.00M	$-112.30M	$-107.69M	$-102.24M	$-93.16M	$-75.24M	$-72.14M	$-66.41M	$-70.48M	$-65.12M	$-16.95M	$-53.75M	$-47.13M	$-44.58M	$-47.89M	$-43.77M	$-27.41M	$-178.77M	$-25.45M	$-15.83M	$1.64M	$-36.00K	$-18.13M
High Forecast	$-123.36M	$-117.41M	$-112.32M	$-106.65M	$-105.19M	$-101.39M	$-93.16M	$-75.24M	$-67.70M	$-63.55M	$-67.66M	$-62.52M	$-13.56M	$-53.75M	$-47.13M	$-44.58M	$-47.89M	$-43.77M	$-27.41M	$-143.01M	$-25.45M	$-15.83M	$1.64M	$-36.00K	$-14.50M
Low Forecast	$-135.99M	$-129.43M	$-123.82M	$-123.33M	$-110.49M	$-103.09M	$-93.16M	$-75.24M	$-76.07M	$-69.27M	$-74.59M	$-68.92M	$-20.34M	$-53.75M	$-47.13M	$-44.58M	$-47.89M	$-43.77M	$-27.41M	$-214.52M	$-25.45M	$-15.83M	$1.64M	$-36.00K	$-21.75M
Surprise %	-	-	-	-	-	-	-	-	-	1.26%	1.27%	1.20%	8.02%	2.35%	2.06%	1.74%	4.38%	2.17%	5.90%	1.29%	2.95%	3.95%	-48.56%	1301.64%	2.49%

undefined analysts predict ZLAB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Zai Lab's previous annual EBITDA (undefined) of $NaN.

Zai Lab Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
# Analysts	1	1	1	3	4	2	2	2	5	2	2	2	1	3	3	3	4	4	4	4	4	4	4	4	3
Net Income	-	-	-	-	-	-	-	-	-	$-69.15M	$-120.89M	$-28.77M	$-26.25M	$-158.96M	$-136.07M	$-84.80M	$-203.94M	$-109.28M	$-155.67M	$-238.92M	$-57.39M	$-50.96M	$-77.02M	$-49.52M	$-40.56M
Avg Forecast	$-31.41M	$-53.50M	$-56.94M	$-58.90M	$-71.63M	$-76.85M	$-69.54M	$-90.80M	$-84.01M	$-102.50M	$-77.59M	$-93.08M	$-17.43M	$-121.87M	$-104.98M	$-122.99M	$-130.17M	$-114.98M	$-103.61M	$-179.89M	$-165.42M	$-165.42M	$-58.10M	$-61.42M	$-18.65M
High Forecast	$-29.78M	$-50.72M	$-53.98M	$-55.84M	$-65.82M	$-72.86M	$-65.92M	$-86.08M	$-75.32M	$-97.17M	$-73.56M	$-88.24M	$-13.95M	$-121.87M	$-104.98M	$-122.99M	$-130.17M	$-114.98M	$-103.61M	$-143.91M	$-165.42M	$-165.42M	$-58.10M	$-61.42M	$-14.92M
Low Forecast	$-33.80M	$-57.56M	$-61.25M	$-63.37M	$-75.50M	$-82.68M	$-74.81M	$-97.68M	$-93.66M	$-110.27M	$-83.47M	$-100.13M	$-20.92M	$-121.87M	$-104.98M	$-122.99M	$-130.17M	$-114.98M	$-103.61M	$-215.86M	$-165.42M	$-165.42M	$-58.10M	$-61.42M	$-22.37M
Surprise %	-	-	-	-	-	-	-	-	-	0.67%	1.56%	0.31%	1.51%	1.30%	1.30%	0.69%	1.57%	0.95%	1.50%	1.33%	0.35%	0.31%	1.33%	0.81%	2.18%

Zai Lab's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ZLAB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Zai Lab SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
# Analysts	1	1	1	3	4	2	2	2	5	2	2	2	1	3	3	3	4	4	4	4	4	4	4	4	3
SG&A	-	-	-	-	-	-	-	-	-	$68.55M	$67.92M	$62.51M	$72.02M	$66.56M	$63.40M	$56.99M	$69.58M	$59.00M	$54.41M	$35.84M	$40.97M	$27.87M	$23.76M	$18.71M	$23.02M
Avg Forecast	$294.45M	$280.25M	$268.10M	$257.33M	$246.77M	$234.28M	$213.48M	$8.42M	$165.31M	$152.17M	$161.50M	$9.00M	$8.65M	$123.16M	$107.98M	$9.63M	$109.75M	$100.31M	$62.80M	$40.46M	$58.32M	$36.28M	$-3.75M	$82.49K	$9.25M
High Forecast	$311.62M	$296.59M	$283.73M	$282.60M	$253.18M	$236.23M	$213.48M	$10.10M	$174.32M	$158.73M	$170.92M	$10.80M	$10.37M	$123.16M	$107.98M	$11.55M	$109.75M	$100.31M	$62.80M	$40.46M	$58.32M	$36.28M	$-3.75M	$82.49K	$11.10M
Low Forecast	$282.68M	$269.04M	$257.38M	$244.38M	$241.03M	$232.34M	$213.48M	$6.73M	$155.14M	$145.62M	$155.05M	$7.20M	$6.92M	$123.16M	$107.98M	$7.70M	$109.75M	$100.31M	$62.80M	$40.46M	$58.32M	$36.28M	$-3.75M	$82.49K	$7.40M
Surprise %	-	-	-	-	-	-	-	-	-	0.45%	0.42%	6.95%	8.33%	0.54%	0.59%	5.92%	0.63%	0.59%	0.87%	0.89%	0.70%	0.77%	-6.33%	226.86%	2.49%

Zai Lab's average Quarter SG&A projection for Dec 23 is $165.31M, based on 5 Wall Street analysts, with a range of $155.14M to $174.32M. The forecast indicates a 141.14% rise compared to ZLAB last annual SG&A of $68.55M (Sep 23).

Zai Lab EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
# Analysts	1	1	1	3	4	2	2	2	5	2	2	2	1	3	3	3	4	4	4	4	4	4	4	4	3
EPS	-	-	-	-	-	-	-	-	-	$-0.71	$-0.00	$-0.30	$-0.27	$-1.66	$-1.42	$-0.89	$-2.15	$-1.15	$-1.67	$-2.70	$-0.65	$-0.68	$-1.03	$-0.68	$-0.56
Avg Forecast	$-0.32	$-0.55	$-0.58	$-0.60	$-0.73	$-0.78	$-0.71	$-0.92	$-0.86	$-1.04	$-0.79	$-0.95	$-1.11	$-1.25	$-1.08	$-1.26	$-1.33	$-1.18	$-1.06	$-1.58	$-1.70	$-1.70	$-0.60	$-0.63	$-0.94
High Forecast	$-0.30	$-0.52	$-0.55	$-0.57	$-0.67	$-0.74	$-0.67	$-0.88	$-0.77	$-0.99	$-0.75	$-0.90	$-1.05	$-1.25	$-1.08	$-1.26	$-1.33	$-1.18	$-1.06	$-1.58	$-1.70	$-1.70	$-0.60	$-0.63	$-0.94
Low Forecast	$-0.34	$-0.59	$-0.62	$-0.65	$-0.77	$-0.84	$-0.76	$-1.00	$-0.95	$-1.12	$-0.85	$-1.02	$-1.19	$-1.25	$-1.08	$-1.26	$-1.33	$-1.18	$-1.06	$-1.58	$-1.70	$-1.70	$-0.60	$-0.63	$-0.94
Surprise %	-	-	-	-	-	-	-	-	-	0.68%	0.00%	0.32%	0.24%	1.33%	1.32%	0.71%	1.61%	0.98%	1.57%	1.71%	0.38%	0.40%	1.73%	1.08%	0.60%

According to undefined Wall Street analysts, Zai Lab's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ZLAB previous annual EPS of $NaN (undefined).

Zai Lab Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
CCCC	C4 Therapeutics	-	-	236.66%	Buy
ZLAB	Zai Lab	-	-	193.77%	Buy
APLS	Apellis Pharmaceuticals	-	-	168.47%	Buy
CGEM	Cullinan Oncology	-	-	157.77%	Buy
ERAS	Erasca	-	-	150.00%	Buy
LEGN	Legend Biotech	-	-	108.03%	Buy
ASND	Ascendis Pharma	-	-	55.10%	Buy
AKRO	Akero Therapeutics	-	-	47.44%	Buy
ROIV	Roivant Sciences	-	-	37.14%	Buy
BPMC	Blueprint Medicines	-	-	13.55%	Buy
PTCT	PTC Therapeutics	-	-	8.42%	Hold
KRYS	Krystal Biotech	-	-	4.78%	Buy
ALNY	Alnylam Pharmaceuticals	-	-	3.00%	Buy
MDGL	Madrigal Pharmaceuticals	-	-	-4.10%	Buy
RXDX	Prometheus Biosciences	-	-	-30.69%	Buy

ZLAB Forecast FAQ

Is Zai Lab a good buy?

Yes, according to 3 Wall Street analysts, Zai Lab (ZLAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of ZLAB's total ratings.

What is ZLAB's price target?

Zai Lab (ZLAB) average price target is $75.5 with a range of $50 to $101, implying a 193.77% from its last price of $25.7. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Zai Lab stock go up soon?

According to Wall Street analysts' prediction for ZLAB stock, the company can go up by 193.77% (from the last price of $25.7 to the average price target of $75.5), up by 293.00% based on the highest stock price target, and up by 94.55% based on the lowest stock price target.

Can Zai Lab stock reach $40?

ZLAB's average twelve months analyst stock price target of $75.5 supports the claim that Zai Lab can reach $40 in the near future.

What are Zai Lab's analysts' financial forecasts?

Zai Lab's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $378.33M (high $381.98M, low $374.98M), average EBITDA is $-378M (high $-375M, low $-382M), average net income is $-309M (high $-291M, low $-331M), average SG&A $702.94M (high $712.99M, low $693.58M), and average EPS is $-3.146 (high $-2.961, low $-3.368). ZLAB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $480.1M (high $512.57M, low $459.74M), average EBITDA is $-480M (high $-460M, low $-513M), average net income is $-201M (high $-190M, low $-216M), average SG&A $1.1B (high $1.17B, low $1.05B), and average EPS is $-2.045 (high $-1.939, low $-2.2).

Did the ZLAB's actual financial results beat the analysts' financial forecasts?

Based on Zai Lab's last annual report (Dec 2023), the company's revenue was $266.72M, which missed the average analysts forecast of $274.15M by -2.71%. Apple's EBITDA was $-367M, beating the average prediction of $-274M by 33.71%. The company's net income was $-335M, missing the average estimation of $-357M by -6.31%. Apple's SG&A was $281.61M, missing the average forecast of $487.99M by -42.29%. Lastly, the company's EPS was $-34.63, beating the average prediction of $-3.638 by 851.80%. In terms of the last quarterly report (Sep 2023), Zai Lab's revenue was $69.23M, beating the average analysts' forecast of $66.41M by 4.24%. The company's EBITDA was $-83.57M, beating the average prediction of $-66.41M by 25.84%. Zai Lab's net income was $-69.152M, missing the average estimation of $-102M by -32.53%. The company's SG&A was $68.55M, missing the average forecast of $152.17M by -54.95%. Lastly, the company's EPS was $-0.71, missing the average prediction of $-1.044 by -32.00%